Why the study?
To determine whether a DCB-only strategy with a new ultrasound-controlled paclitaxel releasing balloon has a similar safety profile and equal angiographic and clinical outcomes to DES implantation in primary STEMI patients.
Does an ultrasound-controlled paclitaxel releasing balloon reduce late lumen loss compared to an asymmetric drug-eluting stent in patients with primary STEMI?
Does an ultrasound-controlled paclitaxel releasing balloon reduce late lumen loss compared to an asymmetric drug-eluting stent in patients with primary STEMI?
A novel ultrasound-controlled paclitaxel-releasing balloon demonstrated similar angiographic late lumen loss and clinical outcomes compared to drug-eluting stents in patients with primary STEMI.
Answers are grounded in this paper and cite their sources.
Comparable late lumen loss supports DCB as an alternative to DES in primary STEMI; extends limited RCT evidence for ultrasound-controlled balloons.
BACKGROUND: Application of drug-coated balloons (DCBs) is popular for the treatment of percutaneous coronary intervention (PCI). A new DCB has been designed as ultrasound-controlled paclitaxel releasing. This study was conducted to determine whether a DCB-only strategy has a similar safety profile and equal angiographic and clinical outcomes to DES implantation in primary ST-elevation myocardial infarction (STEMI) patients, as well as determine the efficiency and safety of this new DCB. METHODS AND RESULTS: Overall, 184 pretreated STEMI patients were randomized into DCB and DES groups with a 1:1 allocation. The main study end-point was late lumen loss (LLL) during the 9 months after PCI. Late lumen loss was reported to be 0.24±0.39 mm in the DCB group and 0.31±0.38 mm in the DES group (P=0.215). Diameter stenosis was 28.27±15.35% in the DCB group and 25.73±15.41% in the DES group (P=0.312). Major adverse cardiovascular events (MACEs) were reported in 3 patients (3.4%) in the DCB group and 4 patients (4.7%) in the DES group (P=0.718). TLR and TVR in the DCB group was 2.3%, 3.4% and 2.4%, 3.5% in the DES group (P=1.000), respectively. No cardiac death and stent thrombosis (ST) was found in the DCB group at 12 months clinical follow up. CONCLUSIONS: The DCB-only strategy showed good angiographic and clinical outcomes in the 9- and 12-month follow-up periods, respectively. The VasoguardTM DCB is safe and feasible to treat STEMI patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: